Abbott Laboratories

  • A Safe Way to Play Emerging Market Growth

    By Justin Carley - August 15, 2013 | Tickers: ABT, EEM, MJN, PM

    The benefits to investing in emerging markets have become well known during the last decade. The pros include better long-term growth and diversification form a portfolio standpoint. The cons are big losses during both cyclical and secular bear markets along with much higher volatility over the cycle. Investors often face this difficult tug-of-war when evaluating whether to invest in emerging markets, and if so, how much. A better alternative might more »

  • Satiate Your Lust for Bucks With These Healthcare Players

    By Narmin Jiwani - August 15, 2013 | Tickers: ABT, ISRG, MDT

    Mankind can’t do without healthcare; we know that; it’s a criminally bare story. Very few industries touch human lives the way healthcare industry does. And, when you consider the growth of the industry which supplies medical devices to the hospitals, the story becomes even more compelling. According to Lucintel, global medical device industry is expected to grow at a CAGR of 6.1% in a six-year period initiating more »

  • China is Tightening its Grip on the Baby Food Industry

    By Gretchen Stone - August 9, 2013 | Tickers: ABT, MJN

    Multinational baby food makers have hit another roadblock in China, as the government begins a three-month campaign to buoy the image and competitiveness of the weakened domestic milk industry. Both were damaged by the 2008 tainted milk scandal that left six babies dead and thousands hospitalized. A business strategist couldn't concoct a better three-point plan: leverage a price-fixing scandal, publicize precautionary recalls and consolidate the domestic market to shut more »

  • A Closer Look at Pfizer’s Three-Way Split

    By Leo Sun - August 7, 2013 | Tickers: ABT, ACT, MRK, PFE, TEVA

    Last week, pharma giant Pfizer (NYSE: PFE) announced that it was planning to split the company into three businesses -- a move that had been long anticipated by analysts and investors alike. Although this move streamlines the company’s core businesses’ financials, does it change anything for investors?

    Prelude to a spin-off

    In its first business segment led by Geno Germano, Pfizer intends to group immunology and metabolic treatments together with more »

  • This Acquisition Will Improve Abbott's Business

    By Kanak Kanti - July 29, 2013 | Tickers: ABT, BCR, COV

    Abbott Laboratories' (NYSE: ABT) bid to acquire IDEV Technologies by end-2013 will strengthen the former’s medical devices (Abbott Vascular) business especially in stent offerings for pulmonary arterial diseases (PAD). Abbott Vascular represents roughly 14% of Abbott's total sales, and that mostly comprises various types of drug eluting stents (DES). However, PAD is another very important type of stent that Abbott does not cover at present. IDEV's expertise more »

  • Healthcare Stocks to Consider Buying

    By David Gould - July 26, 2013 | Tickers: ABT, ABBV, LLY, STJ

    Note: This article has been amended to remove TRADJENTA as Eli Lilly's leading products--it is developed and commercialized through an alliance between Eli Lilly and Boehringer Ingelheim International GmbH & Co

    To address the patent cliff, several large pharmaceutical companies have been actively reinventing their businesses in terms of pipeline updates and strategic changes. Below, I present my take on two leading producers with a focus on the headwinds and more »

  • Two Medical Device Companies Making Smart Acquisitions

    By usman iftikhar - July 24, 2013 | Tickers: ABT, KOOL

    Due to the aging population in developed nations, rising incomes levels in emerging nations, and overall higher government spending in the healthcare sector, the medical industry is expected to earn big profits in the coming years. The players in the industry are striving to derive long term benefits from this highly favorable situation by implementing a variety of new strategies. Currently, the industry leader, Abbott Laboratories (NYSE: ABT) has made more »

  • An Income Portfolio for Retirees

    By Ryan Peckyno - July 22, 2013 | Tickers: MMM, ABT, KO, COP

    A few years ago we hit an unusual milestone in the chronicles of investing: the average dividend yield of the S&P 500 exceeded the yield of the ten-year Treasury note for the first time in more than 50 years. In fact, in 2011, the average dividend yield of the S&P 500 hovered around 3.3 to 3.4 percent, more than half a percent higher than the ten-year more »

  • How Will the Patent Cliff Affect These Pharmaceuticals?

    By Fernando Domenici - July 18, 2013 | Tickers: ABT, MRK, PFE

    The pharmaceutical sector is mainly about the pipeline of new products and patents. The term patent cliff is being used to describe drugs that are near their patent expiration date which is extremely important because after the expiry new generic producers invade the market generating sales and price cuts for those specific drugs. Also, the pipeline of new product development has not been as successful as decades before and this more »

  • Why One of My Favorite Healthcare Companies Is Too Expensive

    By Matthew Frankel - July 15, 2013 | Tickers: ABT, ABBV, HOLX

    Abbott Labs (NYSE: ABT) has been one of the biggest players in the healthcare sector for many years, but a lot of changes have been taking place within the company. Most significantly, Abbott spun off its research-based pharmaceuticals business on the first of the year, creating the new entity AbbVie (NYSE: ABBV). In its current form, Abbott produces nutritionals, diagnostic products, generic medications, and medical devices. With a great balance more »

  • Probing Into Infant Milk May Just Be the Beginning

    By Nick Chiu - July 12, 2013 | Tickers: ABT, MJN, NSRGY

    In early July, in hoping to restore consumers’ confidence, China is investigating several major foreign milk powder sellers for possible price manipulations and breaching of Chinese antitrust law. The pricing of infant formula sold by Abbott Laboratories (NYSE: ABT), Mead Johnson Nutrition (NYSE: MJN), Nestle (NASDAQOTH: NSRGY), Danone, and Royal FrieslandCampina NV are being investigated.

    The bigger picture

    The investigation may be part of China’s broader plan to boost more »

  • Why Investors Should Care About Hepatitis C

    By Nick Chiu - July 9, 2013 | Tickers: ABT, ABBV, ACHN, GILD

    Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver. An estimated 130 million-200 million people worldwide are infected with hepatitis C, and more than 350,000 people die every year from hepatitis C-related liver diseases.


    HCV is the most common chronic blood-borne infection in the United States and the leading cause of liver transplants, according to the Centers for Disease Control and more »

  • Which Infant Formula Stock is a Best Buy Now?

    By Anh HOANG - July 9, 2013 | Tickers: ABT, DANOY.PK, MJN

    I always consider a short-term stock price decline to be an opportunity for investors to accumulate a company’s shares at a low price. Recently, Mead Johnson Nutrition (NYSE: MJN) experienced a significant decline of 8.1% on the market to only $68.85 per share. The huge fall in its stock price was due to the news that China has launched an investigation into possible antitrust violations. Other infant more »

  • Is this Stock the Mother's Milk?

    By Marshall Hargrave - July 8, 2013 | Tickers: ABT, DF, DANOY.PK, MJN

    The major baby formula companies were under pressure last week on reports that China is launching an investigation related to price fixing among the major formula companies. Mead Johnson (NYSE: MJN) is taking the most heat and its stock has fallen off a cliff. 

    <img alt="" src="" />

    It's only fair that Mead Johnson is being pulled down the most, given nearly 80% of its revenues are derived form the Asia and Latin more »

  • Is This Company's Cash Cow Drying Up?

    By Leo Sun - July 6, 2013 | Tickers: ABT, DANOY.PK, MJN, NSRGY

    Shares of Mead Johnson Nutrition (NYSE: MJN) plunged recently, after Chinese regulators stated that they were investigating claims that foreign companies were intentionally overcharging for infant formula to capitalize on fears of domestic contamination of dairy products. Foreign milk-powder companies have raised their prices 30% since 2008, according to China’s state-controlled People’s Daily newspaper.

    Will this investigation derail the growth of Mead Johnson and its industry peers in more »

  • How to Play a Stronger Dollar, or Hedge Against a Falling One

    By Joseph Harry - July 3, 2013 | Tickers: ABT, MO, T, PM

    Back in late March the head of US equity strategy for Deutsche Bank, David Bianco, stated that, "I’d welcome a stronger dollar... It contains the risk of any surge in interest rates, or inflation risk.’’ The statement was in reference to predictions by Deutsche Bank analysts that the dollar would strengthen by as much as 7% against the euro by the year's end. 

    Coming back to the current more »

  • Hedge Fund Brahman Capital Bets Big on This Pharma Stock

    By Meena Krishnamsetty - June 28, 2013 | Tickers: ABT, ENDP, GILD, TEVA

    A 13G filed with the SEC has disclosed that Brahman Capital, a hedge fund managed by Peter Hochfelder and his team, owns 6.3 million shares of Endo Health Solutions (NASDAQ: ENDP), a $4.3 billion market cap pharmaceutical company.

    We track quarterly 13F filings from hedge funds such as Brahman as part of our work researching investment strategies (we have found, for example, that the most popular small cap more »

  • Pharmaceutical industry in trouble?

    By Vanina Egea - June 27, 2013 | Tickers: ABT, MRK, PFE

    The pharmaceutical sector is mainly about pipeline of new products and patents. The term patent cliff is being used to describe drugs that are near their patent expiration date which is extremely important because after the expiry new generic producers invade the market generating sales and prices cuts for those specific drugs. Also, the pipeline of new products development has not been as successful as decades before and this has more »

  • This Healthcare Giant is Definitely a Great Buy Now

    By Anh HOANG - June 25, 2013 | Tickers: ABT, ABBV, JNJ

    I am always excited when a company plans to return more cash to its shareholders in both dividends and share buybacks. Recently, Abbott Laboratories (NYSE: ABT) declared a quarterly dividend of 14 cents per share. Moreover, the company’s board has also authorized a $3 billion share buyback program to replace a $5 billion buyback program that was recently completed. Is Abbott a buy after a recent announcement of both more »

  • This Pharmaceutical Stock Promises Robust Returns

    By Kiran Gulati - June 21, 2013 | Tickers: ABT, TEVA, VRX

    The healthcare sector has always been a subject of great interest to investors and analysts alike. With the rise of sedentary lifestyles and increasing stress levels across demographics, the healthcare sector has a huge market to cater to.

    Valeant Pharmaceuticals (NYSE: VRX) is a fast growing company in dermatology, ophthalmology and neurology. Over the years, Valeant has developed a disparate product portfolio comprising of prescription drugs, branded generics and Over more »

  • Page 1 of 9